Drug Profile
Research programme: glucagon-like peptide-1 receptor modulators - Addex Therapeutics
Alternative Names: GLP-1 PAM; GLP-1R PAMLatest Information Update: 22 Feb 2023
Price :
$50
*
At a glance
- Originator Addex Pharmaceuticals
- Developer Addex Therapeutics
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Glucagon-like peptide 1 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 22 Feb 2023 Discontinued - Preclinical for Type 2 diabetes mellitus in Switzerland (PO) (Addex Pharmaceuticals pipeline, February 2023)
- 28 Jan 2021 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in Switzerland (PO)
- 06 Dec 2016 Preclinical for Type-2 diabetes mellitus in Switzerland (PO) before December 2016 (Addex Therapeutics pipeline, December 2016)